[Effects of raloxifene on other organs without bone: uterus].
Tamoxifen and Toremifene act as agonistic on uterine myometrium and endometrium. Tamoxifen leads re-enlargement of uterine myomas, recurrence of adenomyosis, atypical genital bleeding for endometrial hyperplasia and endometrial carcinoma in postmenopausal women. Therefore, it is necessary to evaluate the stage of pathological change on myometrium and endometrium, both before and during the period of administration of tamoxifen or toremifene. Unlike these drugs, raloxifene has an antagonistic action on uterine myometrium and endometrium. From these standpoints, we consider that raloxifene use lower the risks of uterine myomas, adenomyosis, endometrial hyperplasia and endometrial carcinoma.
Nozaki
Masahiro
M
Department of Obsterics and Gynecology, Graduate School of Medical Sciences, Kyushu University.
D001943:Breast Neoplasms / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D004717:Endometrium / Q000473:pathology; D005260:Female; D006801:Humans; D009215:Myometrium / Q000473:pathology; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D020849:Raloxifene Hydrochloride / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D012306:Risk; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D013629:Tamoxifen / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D014591:Uterine Diseases / Q000139:chemically induced* / Q000473:pathology
D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride